drugset
drugset / Trial / NCT05478772

Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

NCT05478772 ↗

Phase 1 Completed 18 enrolled Concert Pharmaceuticals
NaSingle-groupOpen-labelOther

Summary

A single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to evaluate the effect of multiple doses of Fluconazole, a CYP3A4 and CYP2C9 inhibitor, on the pharmacokinetics (PK) of CTP-543 in healthy subjects

Timeline

Start
2022-07-11
Primary completion
2022-08-06
Completion
2022-08-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-543 Unknown 12 mg Oral
Subject Fluconazole Small molecule 200 mg Oral

Indications

No indication recorded.